Arbutus Biopharma Corp. (NASDAQ:ABUS)’s share price rose 3.1% during trading on Thursday . The company traded as high as $4.05 and last traded at $3.97, with a volume of 83,391 shares traded. The stock had previously closed at $3.85.

Several equities analysts have issued reports on ABUS shares. Zacks Investment Research upgraded shares of Arbutus Biopharma Corp. from a “hold” rating to a “buy” rating and set a $6.00 price objective for the company in a research note on Monday, April 25th. Chardan Capital downgraded shares of Arbutus Biopharma Corp. from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $3.25 to $2.75 in a research note on Friday. Wedbush restated an “outperform” rating and issued a $20.00 price objective on shares of Arbutus Biopharma Corp. in a research note on Wednesday, May 4th. Finally, Leerink Swann restated a “buy” rating and issued a $12.00 price objective on shares of Arbutus Biopharma Corp. in a research note on Thursday, May 5th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. Arbutus Biopharma Corp. has an average rating of “Buy” and a consensus price target of $10.96.

The company’s 50 day moving average price is $3.72 and its 200 day moving average price is $3.94. The firm’s market capitalization is $213.58 million.

Arbutus Biopharma Corp. (NASDAQ:ABUS) last issued its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.20. Equities analysts anticipate that Arbutus Biopharma Corp. will post ($1.49) EPS for the current fiscal year.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.